Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus EPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus EPICORT.
CARMOL HC vs EPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
IV: 50 mg every 8 hours over 30 minutes.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid